secwatch.observer — SEC 8-K summary
======================================

Issuer:     GoodRx Holdings, Inc. (GDRX)
CIK:        0001809519
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001809519-24-000194
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GoodRx Q3 2024 revenue $195.3M, net income $4.0M, Adjusted EBITDA $65.0M
------------------------------------------------------------------------

- Revenue and Adjusted Revenue both $195.3 million for Q3 2024.
- Net income of $4.0 million (2.0% margin); Adjusted Net Income $31.9 million (16.4% margin).
- Adjusted EBITDA $65.0 million (33.3% margin); operating cash flow $86.9 million.
- Exited Q3 with over 7 million consumers of prescription-related offerings.
- Expects ~20% YoY growth in pharma manufacturer solutions for Q4 2024 and 20%+ for FY 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1809519/000180951924000194/0001809519-24-000194-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1809519/000180951924000194/gdrx-20241107.htm
  HTML page:      https://secwatch.observer/filing/0001809519-24-000194

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer